Skip to main content
Caplight Logo









Bioherent

Bioherent

Private
MálagaHealthcare & Life Scienceshttps://bioherent.com/

Last Round

Early Funding

Jul 17, 2025

Total Funding Raised

$5.59M

Company Overview

Bioherent is a deep-tech company that develops next-generation in-vitro diagnostic (IVD) solutions using silicon photonics and proprietary surface chemistry for drug allergy testing.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Biotechnology, Sensors

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Non-AI

Keywords

in-vitro diagnosticIVDdrug allergy testingpoint-of-care testingPOCTsilicon photonicsbiosensorsmedtechdiagnostic platformallergy diagnosticsmicrofluidicsnanotechnologyclinical diagnosticslab-on-a-chipdiagnostic cartridges

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Bioherent Comparables

Compare Bioherent with similar companies based on industry and business-model similarity.

Bioherent comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Allergios
83%
Eroica Dx
75%
Genalyte
69%

Bioherent Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 17, 2025
SeedFeb 25, 2022

Key People

Founding team and executive leadership

Yara Aceta

Chief Executive Officer

Executive Team

Irene Dominguez Barragán

CFO

Executive Team

Bioherent Investors

Notable investors and investment history

Bioherent investors
InvestorRounds
CDTI InnvierteEarly Funding
Axon Partners GroupEarly Funding
Center for Technological Development and InnovationSeed
Bullnet CapitalEarly Funding, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 2823% MoM, from 30 to 877.

  • Nov 7, 2025

    Monthly visitors grew 95% MoM.

Bioherent Filings

Explore SEC and related filing metadata, where available.

Bioherent filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Bioherent's valuation, stock price, and market status.

Is Bioherent a public or private company?

Bioherent is a private company.

What is the current stock price of Bioherent?

Bioherent is a private company with no public stock price. No recent secondary market data is available.

How much is Bioherent worth (valuation)?

Valuation information for Bioherent is not publicly available.

Can I buy Bioherent stock?

Bioherent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Bioherent's last funding round?

Bioherent's most recent funding round was Early Funding on July 17, 2025.

Who are the main investors in Bioherent?

Key investors in Bioherent include Bullnet Capital.

Will Bioherent IPO soon?

No public IPO plans have been announced for Bioherent.

How can I track Bioherent secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Bioherent's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMálaga
Employee Range15
Year Founded2021
Last FundingJul 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?